Celltrion Opens Production Facility in Branchburg, New Jersey, USA

Eliminating Tariff Risks and Strengthening the Global Supply Chain
"Expanding into a Comprehensive CDMO Forward Base"

Celltrion announced on January 6 that it held an opening ceremony on the 5th (local time) at its production facility located in Branchburg, New Jersey, USA.

(From left) Ki Woo-sung, Vice Chairman of Celltrion; Todd Wingji, CEO of Celltrion Branchburg; Kyungok Park, Senior Vice Chairman of Celltrion Holdings; Jungjin Seo, Chairman of Celltrion Group; Andy Kim, U.S. Senator from New Jersey; Thomas Kean Jr., U.S. Representative from New Jersey; Thomas Young, Mayor of Branchburg Township; and Junseok Seo, Head of Celltrion North America Headquarters, are cutting the ribbon at the opening ceremony held on the 5th (local time) at the production facility located in Branchburg, New Jersey, USA. Celltrion

This opening ceremony was the first official event held since Celltrion completed the acquisition of the Branchburg facility at the end of last year. The event was attended by key guests, including Andy Kim, U.S. Senator from New Jersey; Thomas Kean Jr., U.S. Representative from New Jersey; Thomas Young, Mayor of Branchburg Township; as well as Celltrion’s management team.

Jungjin Seo, Chairman of Celltrion Group, who attended the ceremony, delivered a welcoming address, stating, “We plan to expand the Branchburg production facility into a comprehensive contract development and manufacturing organization (CDMO) production base, including a future research center, so that it will serve as a major pillar of Celltrion’s global growth alongside our Songdo headquarters.”

In addition, Chairman Seo appointed Todd Wingji as the new CEO of Branchburg.

With the opening of the Branchburg production facility, Celltrion has eliminated tariff risks and established a stable production and supply system in the United States, thereby strengthening its global production network capabilities. In particular, by acquiring the cGMP (current Good Manufacturing Practice) facility previously operated by Eli Lilly, the company has minimized both the opportunity costs and risks associated with securing a new base.

Furthermore, Celltrion completed a contract manufacturing organization (CMO) agreement for biopharmaceutical drug substance (DS) with Eli Lilly and ensured the succession of local skilled employees, thereby securing continuity in production and operational stability immediately after the acquisition.

Going forward, Celltrion plans to use this facility as a strategic hub, gradually expanding its CMO and CDMO business for global pharmaceutical companies. In addition, the company intends to enhance its business structure by linking local U.S. production capabilities with a direct sales system and to continuously create new business opportunities.

A Celltrion official stated, “The opening of the Branchburg production facility is more than just securing a production base in the United States; it marks a significant turning point in advancing our global production and supply system. Through local production, we will completely eliminate tariff risks and strengthen our competitiveness in the global CDMO business, ensuring a seamless leap forward as a global big pharma.”